`r-—z.s:_a.ua¢»v-A-nan.-m.a-can--nnsn-caau-uuuaa-o«..4 >.-. iezxmaaa--nsa-coma-noun-snunuuuu :7-‘my...,..;._...--- ma»M
`am.-nuoxnnnga-names: -mmmm~.
`_ a -°;fi°se«-,2-Tl._a.;.'.-.v»...¢-uana...1~,~an:ee-ran-u;n<.7:v:vrm:vxvvws-.s.
`, ..m~.\-.»_‘..‘,,,;..;=v-nu-v:a~r.:-.-u-»;.-m-.-nu<-rap.--ax---mu. :;:rm:.-.mmv e
`
`From:
`To:
`Date:
`Subject:
`
`Mr. Alex Bossi.
`
`"Baoci. John [OBl]' <JBaoci@obius.jnj.com>
`"'BA@he|sinn.com" <BA@heisinn.com>
`31.05.00 15.41.55
`Paionoselron
`
`)efi—o24«
`O IZTH-O
`2‘-o‘TEE
`9 ‘ 0&1
`E 2/ «A
`
`'
`
`Good afternoon. asl mentioned in my last e-mail. your information
`regarding the improved 5HT3 (Palonosetron) was forwarded to our Oncioogy
`Franchise beam for their assessment The purpose ofthis e-mal is to share
`with you their findings.
`
`/-\
`,3 \,
`V;/>'Ji
`_. 2
`
`5;
`
`At this time. there is low interest to pursue this opportunity further. This
`position is primarily driven from the commercial perspective: 42.9.,
`the
`current 5i-iT3's are viewed as interchangeable in the US; oommodrty pricing
`has set in; generics wil launch in probably the next 5 years; ASCO is
`recommending a lower dose to manage the oncology patient and there is s
`shift to oral from the N.
`Alex. thank you again for thinking about us as a potential interested
`partner and if you have any questions. please do not hesitate to call.
`jdb
`
`HIGHLY CONFIDENTIAL - OUTSIDE COUNSEL EYES ONLY
`
`HELSN0395213
`
`Page 1 0“
`
`Helsinn Healthcare Exhibit 2059
`
`Dr. Reddy's Laboratories, Ltd., et al. v. Helsinn Healthcare S.A.
`Trial PGR2016—00007
`
`PTX-024